Cargando…
Weight gain during the dolutegravir transition in the African Cohort Study
INTRODUCTION: Dolutegravir (DTG) has become a preferred component of first‐line antiretroviral therapy (ART) in many settings but may be associated with excess weight gain. We evaluated changes in weight and body mass index (BMI) after switch to single‐tablet tenofovir/lamivudine/dolutegravir (TLD)...
Autores principales: | Esber, Allahna L., Chang, David, Iroezindu, Michael, Bahemana, Emmanuel, Kibuuka, Hannah, Owuoth, John, Singoei, Valentine, Maswai, Jonah, Dear, Nicole F., Crowell, Trevor A., Polyak, Christina S., Ake, Julie A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008168/ https://www.ncbi.nlm.nih.gov/pubmed/35419973 http://dx.doi.org/10.1002/jia2.25899 |
Ejemplares similares
-
Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study
por: Esber, Allahna, et al.
Publicado: (2022) -
Routine HIV clinic visit adherence in the African Cohort Study
por: Dear, Nicole, et al.
Publicado: (2022) -
1479. Analysis of Depression in People Living with Human Immunodeficiency Virus (HIV) During the Coronavirus Disease 2019 Pandemic in 4 African Countries
por: Adjei, Paul, et al.
Publicado: (2023) -
Prevalence and risk factors associated with HIV and syphilis co-infection in the African Cohort Study: a cross-sectional study
por: Gilbert, Laura, et al.
Publicado: (2021) -
1540. Prevalence and Risk Factors associated with HIV and Syphilis Co-infection in the African Cohort Study
por: Gilbert, Laura, et al.
Publicado: (2020)